CVS Caremark to Cover Lilly's Zepbound on Oct.1 and Foundayo on June1
CVS•CVS Caremark will reinstate coverage of Eli Lilly's Zepbound injectable on October 1 and add its Foundayo weight-loss pill on June 1 for plan members. This move makes CVS the third major PBM, after Optum and Express Scripts, to cover Lilly's GLP-1 weight-loss medications.
1. Coverage Details
CVS Caremark will reinstate preferred formulary status for Eli Lilly’s Zepbound injectable starting October 1 and will introduce coverage for Lilly’s Foundayo weight-loss pill on June 1. Both medications will appear on the standard plan template available to insurers and employers for their private insurance members.
2. PBM Market Context
With this update, CVS joins UnitedHealth’s Optum and Cigna’s Express Scripts as the only major pharmacy benefit managers covering Eli Lilly’s GLP-1 weight-loss offerings. Novo Nordisk’s Wegovy remains on CVS Caremark’s preferred formulary without interruption, ensuring broad optionality for plan sponsors.
3. Financial Implications
Employers and insurers face rising pharmacy spend driven by GLP-1 drugs, which grew nearly 15% in 2026 for a typical family of four. Enhanced coverage could bolster CVS Caremark’s competitive positioning and drive increased utilization fees, potentially boosting its PBM segment revenue.
